Secondary Osteoporosis Causes and Screening

Secondary Osteoporosis Causes — scientific infographic poster
🦴 Interactive Visualization Bone Remodeling & Calcium Balance Watch osteoclasts tunnel and osteoblasts rebuild — then drop vitamin D and see parathyroid hormone (PTH) quietly strip calcium out of your skeleton. Launch →

Table of Contents

  1. What Secondary Osteoporosis Means
  2. Who Is Screened for Secondary Causes
  3. Glucocorticoid-Induced Osteoporosis (GIOP)
  4. Hyperparathyroidism — Primary and CKD-MBD
  5. Hyperthyroidism and Over-Replacement
  6. Hypogonadism in Men — Including ADT
  7. Hypogonadism in Women — Amenorrhea, POI, Turner
  8. Celiac Disease and Inflammatory Bowel Disease
  9. Post-Gastric-Bypass and Bariatric Bone Loss
  10. Anorexia Nervosa and the Female Athlete Triad / RED-S
  11. Multiple Myeloma and Other Malignancies
  12. Chronic Kidney Disease and Renal Osteodystrophy
  13. The Diabetes Paradox — T1D and T2D
  14. Aromatase Inhibitors and ADT for Cancer
  15. Selective Serotonin Reuptake Inhibitors, Proton Pump Inhibitors, and Other Medications
  16. Alcohol and Tobacco
  17. The Screening Lab Panel
  18. Treating the Cause, Not Just the Bone
  19. Key Research Papers
  20. Connections
  21. Featured Videos

What Secondary Osteoporosis Means

"Primary" osteoporosis is what happens to most postmenopausal women and older men: estrogen or testosterone declines, bone turnover shifts toward resorption, and the skeleton slowly thins. "Secondary osteoporosis" means a specific, identifiable disease or medication is driving the bone loss — not just age and hormones.

This distinction matters because secondary causes are treatable, often with dramatic bone recovery once the underlying problem is addressed. A 32-year-old with vertebral fractures is not going through early menopause — she might have untreated celiac disease, an eating disorder, or a pituitary tumor driving cortisol excess. A 55-year-old man with a hip fracture after a minor fall is not just "unlucky" — he may have low testosterone, undiagnosed multiple myeloma, or years of proton-pump-inhibitor use.

Studies of osteoporosis referral clinics consistently find that 20–30% of postmenopausal women and up to 50–60% of men diagnosed with osteoporosis have at least one secondary cause. In premenopausal women and younger men, the proportion is even higher. When osteoporosis is treated with a bisphosphonate alone and no secondary workup is done, a treatable cause can go unfound and keep driving bone loss.

Who Is Screened for Secondary Causes

The Endocrine Society, American College of Rheumatology, and American Association of Clinical Endocrinologists broadly agree that secondary causes are looked for in anyone with osteoporosis whose presentation does not fit a simple age-plus-menopause story. Red flags include:

Glucocorticoid-Induced Osteoporosis (GIOP)

Prednisone, prednisolone, methylprednisolone, dexamethasone, and their inhaled or injected cousins are the single most common cause of drug-induced osteoporosis. GIOP is also the fastest — trabecular bone (the spongy bone in vertebrae and the hip neck) can lose 6–12% in the first year of high-dose therapy, most of it in the first three to six months.

The threshold is lower than patients expect. Meaningful bone loss begins at 2.5–7.5 mg of prednisone daily continued for three months or more. "Low-dose" maintenance prednisone for rheumatoid arthritis, polymyalgia rheumatica, asthma, or inflammatory bowel disease (IBD) is enough to push the skeleton into negative balance. Even intermittent high-dose bursts (pulse steroids for lupus flares, repeated epidural injections) accumulate risk.

Glucocorticoids cause bone loss by three mechanisms at once: they suppress osteoblast bone-formation activity, prolong osteoclast bone-resorption lifespan, and reduce intestinal calcium absorption while increasing urinary calcium loss. The result is a skeleton that both builds less and tears down more, with a calcium deficit on top.

ACR 2022 GIOP guideline. The American College of Rheumatology updated its steroid-bone guideline in 2022 (published in 2023), replacing the 2017 version. It covers people taking glucocorticoids ≥ 2.5 mg/day for more than three months. For adults it strongly recommends a fracture-risk assessment as soon as possible after the steroid is started: a check for past fractures, a bone density scan with vertebral fracture assessment or a spine x-ray, and FRAX for people aged 40 or older. Risk is calculated with FRAX adjusted upward for steroid dose (see the FRAX article). For adults at medium, high, or very high fracture risk, the guideline strongly recommends bone medicine; the choice among oral or intravenous bisphosphonates, denosumab, or parathyroid hormone analogs is left to shared decision-making between patient and clinician, and bone-building (anabolic) drugs are conditionally recommended as the first treatment for people at high and very high risk. It also adds new recommendations on stopping osteoporosis therapy and on switching from one bone drug to another (sequential therapy). The earlier 2017 guideline defined high-risk adults as those with a prior fragility fracture, T-score ≤ −2.5, or FRAX 10-year major osteoporotic fracture risk ≥ 20% / hip risk ≥ 3%, and recommended bone medicine for them.

First-line treatment options:

Whenever possible, the best GIOP treatment is dose reduction or replacement of the steroid. Steroid-sparing biologics in rheumatoid arthritis (RA), inflammatory bowel disease, and asthma have made this much more achievable than it was twenty years ago.

Hyperparathyroidism — Primary and CKD-MBD

The parathyroid glands — four pea-sized glands behind the thyroid — pump out parathyroid hormone (PTH) whenever blood calcium drops. Parathyroid hormone pulls calcium out of bone to restore serum levels. Chronic parathyroid hormone excess chronically strip-mines the skeleton, with a special preference for cortical bone (the dense outer shell of long bones, like the radius at the wrist).

Primary hyperparathyroidism is usually caused by a single benign adenoma in one of the four glands, more common in women over 50. The classic blood picture is high calcium with inappropriately high or normal parathyroid hormone. Many patients are asymptomatic and picked up on routine labs; others develop kidney stones, fatigue, constipation, depression, or osteoporosis. Surgical removal of the overactive gland (parathyroidectomy) reverses bone loss — patients often gain 5–10% BMD over the first two years after surgery.

CKD-MBD (chronic kidney disease – mineral and bone disorder) is secondary hyperparathyroidism driven by failing kidneys: low calcitriol, high phosphate, and low calcium trigger chronic parathyroid hormone elevation. This is a separate beast with its own treatment ladder — phosphate binders, active vitamin D analogues (calcitriol, paricalcitol), and calcimimetics (cinacalcet). Standard bisphosphonate dosing is usually contraindicated when glomerular filtration rate is below 30. See the Kidney Disease page for the broader CKD-MBD picture.

Hyperthyroidism and Over-Replacement

Thyroid hormone directly accelerates bone turnover. When levels run high — whether from Graves' disease, toxic multinodular goiter, or over-replacement with levothyroxine in someone being treated for hypothyroidism — resorption outpaces formation and bone thins quickly.

The risk is not limited to overt disease. Subclinical hyperthyroidism (suppressed thyroid-stimulating hormone (TSH) with normal free T4) carries measurable fracture risk, particularly in postmenopausal women. A thyroid-stimulating hormone level that stays below about 0.3–0.5 mIU/L on levothyroxine is the range linked to bone loss, and outside of deliberate suppression it usually means the dose is more than the body needs. Some thyroid-cancer survivors are kept low-TSH on purpose, and their bones carry the same extra risk.

For context on thyroid diseases in general, see Graves' disease and Hashimoto's thyroiditis (Hashimoto's patients become osteoporosis-relevant only when they are over-replaced).

Hypogonadism in Men — Including ADT

Testosterone supports bone in two ways: directly, through androgen receptors on osteoblasts, and indirectly, by being aromatized to estradiol — and estradiol turns out to be the dominant skeletal hormone in men too. Men with low testosterone lose bone steadily.

Common causes of male hypogonadism include: primary testicular failure (Klinefelter syndrome, prior mumps orchitis, testicular trauma, chemotherapy), pituitary dysfunction (prolactinomas, non-functioning adenomas, hemochromatosis), chronic opioid use, heavy long-term alcohol use, obesity-related secondary hypogonadism, and — most dramatically — androgen deprivation therapy (ADT) for prostate cancer.

ADT and bone. Leuprolide, goserelin, and degarelix shut down testosterone production almost completely; the newer drugs abiraterone (which blocks androgen production) and enzalutamide (which blocks the androgen receptor) are added on top. Men on ADT lose bone at 4–7% in the first year, with fracture risk roughly doubling over a few years. Bone care at the start of ADT usually includes a baseline DEXA, adequate calcium/vitamin D, and — if the planned duration is beyond six to twelve months — consideration of denosumab 60 mg every 6 months or zoledronate. Denosumab at 60 mg has a specific U.S. Food and Drug Administration (FDA) indication for this population.

For non-cancer hypogonadism, treatment of the underlying cause (testosterone replacement when appropriate, opioid weaning, weight loss in obesity-related cases) often reverses bone loss. Low testosterone is usually confirmed with at least two morning fasting total-testosterone measurements before the diagnosis is made, because single random levels swing too much to trust.

Hypogonadism in Women — Amenorrhea, POI, Turner

Estrogen is the master regulator of female bone mass. Any state that removes it for months to years produces measurable bone loss, and the younger the patient, the bigger the eventual deficit — because peak bone mass (usually reached by the late 20s) is itself incomplete.

For a woman in her 20s or 30s who has not menstruated for six months or more and is not pregnant or on hormonal contraception, the usual workup is follicle-stimulating hormone (FSH), luteinizing hormone (LH), prolactin, thyroid-stimulating hormone, estradiol, and a pregnancy test, followed, depending on findings, by estrogen restoration — whether combined oral contraceptive, transdermal estradiol plus progesterone, or causal treatment of the underlying driver.

Celiac Disease and Inflammatory Bowel Disease

Gut disease wrecks bones through several simultaneous routes: impaired absorption of calcium and vitamin D, chronic inflammatory cytokines (tumor necrosis factor-α, interleukin-6 (IL-6)) that directly activate osteoclasts, low body weight, and — in inflammatory bowel disease — repeated courses of glucocorticoids.

Celiac disease. Up to 40–70% of untreated celiac patients have osteopenia or osteoporosis at diagnosis, and the figure is striking even in patients whose gastrointestinal symptoms are mild or silent. A 2019 systematic review limited to men and premenopausal women with celiac disease (563 people; studies that ignored age and menopause were left out) found osteoporosis in 14.4% and osteopenia in 39.6%. Many adults present with fragility fractures or unexplained osteoporosis and only later discover their celiac disease. In a 2015 meta-analysis of prospective studies, diagnosed celiac disease was linked to a 30% increase in the risk of any fracture and a 69% increase in the risk of hip fracture. Celiac blood tests (serology) are part of the standard workup for premenopausal women and men under 50 with unexplained osteoporosis — tissue transglutaminase immunoglobulin A (tTG-IgA) plus total immunoglobulin A (IgA). A 2018 meta-analysis of 3,188 people with osteoporosis found biopsy-confirmed celiac disease in about 1 in 62 (1.6%), similar to the general population; its authors wrote that this argues against routinely screening everyone with osteoporosis for celiac disease, which is contrary to current guideline recommendations. A strict gluten-free diet restores most of the lost bone over two to five years. See the celiac disease page for the full diagnostic and dietary picture.

Inflammatory bowel disease. Both Crohn's disease and ulcerative colitis cause bone loss, but Crohn's is worse because of small-bowel involvement, higher cumulative steroid exposure, and more frequent surgical resections that impair calcium, vitamin D, and magnesium absorption. Between 30% and 60% of inflammatory bowel disease patients have low bone density. Nutrient deficiencies, chronic inflammation, undernutrition, and steroid bursts all contribute — see the inflammatory bowel disease overview and the inflammatory bowel disease nutrient deficiency deep-dive. Shifting from steroid-dependent regimens to biologic therapy (infliximab, adalimumab, ustekinumab, vedolizumab) reduces both inflammation and steroid exposure — and both protect bone.

Post-Gastric-Bypass and Bariatric Bone Loss

Roux-en-Y gastric bypass (RYGB) and biliopancreatic diversion bypass the duodenum and proximal jejunum — the main sites of calcium, iron, and fat-soluble vitamin absorption — and rapidly produce secondary hyperparathyroidism, vitamin D deficiency, and bone loss. Hip-neck BMD drops 8–14% in the first two years after RYGB, and fracture risk rises over the subsequent decade.

Sleeve gastrectomy is gentler but not neutral. Standard bariatric aftercare includes lifelong calcium citrate 1200–1500 mg/day (split doses; citrate is better absorbed than carbonate with low stomach acid), vitamin D 3000 international units/day or more titrated to a 25-OH-D above 30 ng/mL, and a bariatric-specific multivitamin. Annual labs and a baseline-plus-follow-up DEXA are standard of care.

Anorexia Nervosa and the Female Athlete Triad / RED-S

Anorexia nervosa causes some of the most severe osteoporosis seen in young people. The mechanism is multi-hit: low body weight, hypothalamic amenorrhea (estrogen withdrawal), low insulin-like growth factor 1 (IGF-1), elevated cortisol, and frank calcium/vitamin D deficiency. Over 50% of adult women with anorexia have osteoporosis; fracture risk is two to seven times higher than age-matched controls.

The female athlete triad — low energy availability, menstrual dysfunction, low bone density — and its broader relabeling as RED-S (Relative Energy Deficiency in Sport) describe the same physiology in athletes: under-fueling relative to training demands shuts down the hypothalamic-pituitary-ovarian axis. Distance runners, gymnasts, ballet dancers, and lightweight rowers are classically at risk, but the pattern appears in any sport where leanness is rewarded.

Treatment is weight restoration and resumption of menses, not a bisphosphonate. Oral contraceptives do not reliably protect bone in this population because they do not restore the metabolic milieu (insulin-like growth factor 1, leptin). Transdermal estradiol plus cyclic progesterone has modest evidence of benefit during recovery, and teriparatide has been used in severe adult cases with ongoing fractures. The definitive treatment is eating enough.

A 2014 review by Misra and Klibanski sets out the evidence in plain terms: regaining weight and menstrual periods is the best way to improve bone density; oral estrogen-progesterone combinations do not raise bone density in adults or teenagers with anorexia, and testosterone given through the skin does not raise it in adult women. Estrogen given as a skin patch (transdermal estradiol) with cyclic progesterone raised the rate of bone gain in teenagers with anorexia to about that of normal-weight peers. One study found that risedronate raised spine and hip bone density in adult women with anorexia, but the review warns that bisphosphonates stay in the body for years and may harm a developing baby, a concern for women who may become pregnant; it describes them as a choice only for low bone density with significant fractures when weight-gain treatment has not worked.

Multiple Myeloma and Other Malignancies

Multiple myeloma is a plasma-cell malignancy that produces osteoclast-activating factors and is classically heralded by unexplained osteoporosis, vertebral compression fractures, bone pain, or lytic lesions on imaging. For anyone over 40 with unexplained osteoporosis — especially if paired with anemia, elevated total protein, hypercalcemia, or kidney dysfunction — the standard check is serum and urine protein electrophoresis (SPEP/UPEP) with immunofixation plus serum free light chains.

Other malignancies that drive bone loss: metastatic breast and prostate cancer (both through direct metastasis and through the hormone therapies discussed below), mastocytosis (mast cells secrete heparin and other osteoclast activators), and a smaller list of leukemias/lymphomas. Any atypical osteoporosis pattern — focal lesions, rapid progression, associated systemic symptoms — warrants oncologic workup.

Chronic Kidney Disease and Renal Osteodystrophy

As glomerular filtration rate falls below 60 mL/min/1.73m2, the kidneys lose the ability to activate vitamin D (convert 25-OH-D to 1,25-diOH-D) and to excrete phosphate. The result is secondary hyperparathyroidism, abnormal mineralization, and a specific renal osteodystrophy pattern that is not simply "osteoporosis."

Practical implications: standard DEXA T-scores behave unreliably below glomerular filtration rate 30; bone biopsy is sometimes needed; most bisphosphonates are contraindicated below glomerular filtration rate 30–35; denosumab works at any glomerular filtration rate but carries an increased risk of profound hypocalcemia that requires careful calcium and calcitriol replacement. Chronic kidney disease (CKD) bone disease is a nephrologist's game — see the Kidney Disease overview.

The Diabetes Paradox — T1D and T2D

Diabetes and bone have a confusing relationship that has taken decades to unravel.

Type 1 diabetes clearly reduces bone density. Insulin itself is an anabolic hormone for bone, and the long years of insufficient insulin action in T1D — plus frequent childhood onset before peak bone mass is established — lead to lower BMD and a much higher hip fracture risk than non-diabetic peers: a 2020 meta-analysis update (42 studies in the hip-fracture analysis, 17,571,738 participants) found a relative risk of 4.93 for hip fracture in type 1 diabetes.

Type 2 diabetes is the paradox. BMD on DEXA is often normal or even slightly increased in T2D, yet fracture risk is 20–60% higher at any given BMD. The bone looks okay on paper but breaks anyway. Why? T2D bone has impaired collagen cross-linking from advanced glycation end-products (AGEs), reduced bone turnover, and microarchitectural defects that DEXA cannot see. FRAX underestimates risk in T2D — one approach used is to read these patients' bone density as one T-score category worse than the scanner reports, or to use the trabecular bone score (TBS) when available. The same 2020 meta-analysis found a relative risk of 1.33 for hip fracture in type 2 diabetes, and in type 2 diabetes the risk was higher with longer diabetes duration and with insulin use.

Certain diabetes drugs matter: thiazolidinediones (pioglitazone, rosiglitazone) increase fracture risk, a concern for anyone with low bone density. Sodium-glucose cotransporter-2 (SGLT2) inhibitors have had mixed signals — canagliflozin showed an early fracture signal in one major trial, though later data are reassuring. Metformin, dipeptidyl peptidase-4 (DPP-4) inhibitors, and glucagon-like peptide-1 (GLP-1) agonists appear neutral or bone-protective.

Aromatase Inhibitors and ADT for Cancer

Aromatase inhibitors (anastrozole, letrozole, exemestane) are the standard adjuvant hormonal therapy for postmenopausal hormone-receptor-positive breast cancer. They block the peripheral conversion of androgens to estrogen, producing near-zero circulating estradiol. The bone consequence is the same as surgical menopause, on top of whatever postmenopausal loss has already occurred. In the ATAC trial's bone substudy, median bone density fell 6.08% at the lumbar spine and 7.24% at the total hip over five years of anastrozole, while it rose on tamoxifen (+2.77% and +0.74%); no woman with normal bone density at the start became osteoporotic by five years. The authors concluded that women with pre-existing osteopenia are likely to need monitoring and bone protection, while women with normal bone density at the start would not appear to need monitoring beyond that recommended for healthy postmenopausal women.

Bone checks at the start of aromatase-inhibitor treatment usually include a baseline DEXA and calcium/vitamin D, and — if FRAX or the treating oncologist identifies elevated risk — either denosumab 60 mg every 6 months or zoledronate 4 mg intravenous every 6 months (the oncology dosing, separate from the osteoporosis 5 mg yearly). ADT in prostate cancer follows the same framework (see the men's hypogonadism section above).

Selective Serotonin Reuptake Inhibitors, Proton Pump Inhibitors, and Other Medications

Several common medications have modest but real effects on bone:

Alcohol and Tobacco

Alcohol. Intakes above three standard drinks per day raise fracture risk substantially, both by direct osteoblast toxicity and through falls, malnutrition, and liver disease. Below two drinks per day the effect on bone is small. Binge patterns are worse than steady low-level drinking.

Tobacco. Current smokers have roughly 25–30% higher hip fracture risk. Mechanisms include direct osteoblast toxicity, reduced estrogen bioavailability, lower body weight, poor nutrition, and impaired fracture healing. Risk starts dropping within a year of quitting and approaches never-smoker levels after about a decade. Both alcohol and smoking are line items inside FRAX — they shift your 10-year fracture probability upward automatically.

The Screening Lab Panel

A reasonable screening panel for secondary causes in any newly diagnosed osteoporosis patient (yield varies but is clinically meaningful in most cohorts):

Not every test is needed for every patient; the history steers the panel. But the first six bullets (CBC, CMP, PTH, 25-OH-D, TSH, SPEP/UPEP) are defensible as a baseline for nearly everyone.

Treating the Cause, Not Just the Bone

The payoff of secondary-cause screening is that treating the underlying condition often restores bone density without any osteoporosis-specific medication:

Pharmacologic therapy (bisphosphonate, denosumab, teriparatide, romosozumab) is still frequently needed when the damage is already severe or the cause cannot be fully reversed. But skipping the cause hunt means fighting the fire without turning off the gas.

Key Research Papers

Society guidelines and pivotal studies covering the dominant secondary causes of low bone mass: glucocorticoid-induced osteoporosis (ACR), male osteoporosis, primary hyperparathyroidism, ADT and aromatase-inhibitor bone loss, type-2 diabetes fragility, celiac disease, anorexia nervosa, and proton pump inhibitor exposure.

  1. Humphrey MB, Russell L, Danila MI, et al. 2022 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis & Rheumatology. 2023;75(12):2088–2102. — PubMed PMID: 37845798
  2. Buckley L, Guyatt G, Fink HA, et al. 2017 American College of Rheumatology Guideline for the Prevention and Treatment of Glucocorticoid-Induced Osteoporosis. Arthritis & Rheumatology. 2017;69(8):1521–1537. — doi:10.1002/art.40137
  3. Watts NB, Adler RA, Bilezikian JP, et al. Osteoporosis in Men: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2012;97(6):1802–1822. — doi:10.1210/jc.2011-3045
  4. Bilezikian JP, Brandi ML, Eastell R, et al. Guidelines for the Management of Asymptomatic Primary Hyperparathyroidism: Summary Statement from the Fourth International Workshop. Journal of Clinical Endocrinology & Metabolism. 2014;99(10):3561–3569. — doi:10.1210/jc.2014-1413
  5. Khosla S, Amin S, Orwoll E. Osteoporosis in Men. Endocrine Reviews. 2008;29(4):441–464. — doi:10.1210/er.2008-0002
  6. Smith MR, Egerdie B, Hernández Toriz N, et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. New England Journal of Medicine. 2009;361(8):745–755. — doi:10.1056/NEJMoa0809003
  7. de Bono JS, Logothetis CJ, Molina A, et al. Abiraterone and increased survival in metastatic prostate cancer. New England Journal of Medicine. 2011;364(21):1995–2005. — PubMed PMID: 21612468
  8. Scher HI, Fizazi K, Saad F, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. New England Journal of Medicine. 2012;367(13):1187–1197. — PubMed PMID: 22894553
  9. Eastell R, Adams JE, Coleman RE, et al. Effect of Anastrozole on Bone Mineral Density: 5-Year Results from the Anastrozole, Tamoxifen, Alone or in Combination Trial 18233230. Journal of Clinical Oncology. 2008;26(7):1051–1057. — doi:10.1200/jco.2007.11.0726
  10. Napoli N, Chandran M, Pierroz DD, Abrahamsen B, Schwartz AV, Ferrari SL. Mechanisms of Diabetes Mellitus-Induced Bone Fragility. Nature Reviews Endocrinology. 2017;13(4):208–219. — doi:10.1038/nrendo.2016.153
  11. Schwartz AV, Vittinghoff E, Bauer DC, et al. Association of BMD and FRAX Score with Risk of Fracture in Older Adults with Type 2 Diabetes. JAMA. 2011;305(21):2184–2192. — doi:10.1001/jama.2011.715
  12. Vilaca T, Schini M, Harnan S, Sutton A, Poku E, Allen IE, Cummings SR, Eastell R. The risk of hip and non-vertebral fractures in type 1 and type 2 diabetes: a systematic review and meta-analysis update. Bone. 2020;137:115457. — PubMed PMID: 32480023
  13. Heikkilä K, Pearce J, Mäki M, Kaukinen K. Celiac disease and bone fractures: a systematic review and meta-analysis. Journal of Clinical Endocrinology & Metabolism. 2015;100(1):25–34. — PubMed PMID: 25279497
  14. Laszkowska M, Mahadev S, Sundström J, Lebwohl B, Green PHR, Michaelsson K, Ludvigsson JF. Systematic review with meta-analysis: the prevalence of coeliac disease in patients with osteoporosis. Alimentary Pharmacology & Therapeutics. 2018;48(6):590–597. — PubMed PMID: 29984519
  15. Ganji R, Moghbeli M, Sadeghi R, Bayat G, Ganji A. Prevalence of osteoporosis and osteopenia in men and premenopausal women with celiac disease: a systematic review. Nutrition Journal. 2019;18(1):9. — PubMed PMID: 30732599
  16. Misra M, Klibanski A. Anorexia Nervosa and Bone. Journal of Endocrinology. 2014;221(3):R163–R176. — doi:10.1530/JOE-14-0039
  17. Yu EW, Bauer SR, Bain PA, Bauer DC. Proton Pump Inhibitors and Risk of Fractures: A Meta-Analysis of 11 International Studies. American Journal of Medicine. 2011;124(6):519–526. — doi:10.1016/j.amjmed.2011.01.007
  18. Mountjoy M, Sundgot-Borgen J, Burke L, et al. The IOC Consensus Statement: Beyond the Female Athlete Triad — Relative Energy Deficiency in Sport (RED-S). British Journal of Sports Medicine. 2014;48(7):491–497. — doi:10.1136/bjsports-2014-093502
  19. Shoback D, Rosen CJ, Black DM, Cheung AM, Murad MH, Eastell R. Pharmacological Management of Osteoporosis in Postmenopausal Women: An Endocrine Society Guideline Update. Journal of Clinical Endocrinology & Metabolism. 2020;105(3):587–594. — doi:10.1210/clinem/dgaa048

PubMed Topic Searches

Live PubMed queries that update as new papers are indexed.

  1. PubMed: glucocorticoid-induced osteoporosis
  2. PubMed: primary hyperparathyroidism BMD
  3. PubMed: celiac disease osteoporosis
  4. PubMed: ADT and bone loss
  5. PubMed: aromatase inhibitor bone loss
  6. PubMed: T2D fracture paradox
  7. PubMed: bariatric surgery bone loss
  8. PubMed: anorexia nervosa BMD
  9. PubMed: PPI and fracture risk
  10. PubMed: myeloma as osteoporosis

Back to Table of Contents

Connections

Back to Table of Contents